Literature DB >> 16540364

Cytokines in head and neck cancer.

Ralph Pries1, Barbara Wollenberg.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent cancers in the world. Standard treatment has only marginally improved the 5-year survival rate of patients with HNSCC in the last 40 years. Alterations in immune, inflammatory as well as angiogenetic responses within the HNSCC microenvironment play a critical role in tumor aggressiveness and its response to chemo- and radiation therapies as well as its influence on the immune system. Therefore, the better understanding of secretion and regulation pathways of immune suppressive and proangiogenic cytokines in HNSCC is essential to increase the clinical perspective of this tumor type with respect to an immunomodulatory intervention in patients with HNSCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540364     DOI: 10.1016/j.cytogfr.2006.02.001

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  39 in total

Review 1.  Control of cytokine mRNA expression by RNA-binding proteins and microRNAs.

Authors:  V Palanisamy; A Jakymiw; E A Van Tubergen; N J D'Silva; K L Kirkwood
Journal:  J Dent Res       Date:  2012-02-01       Impact factor: 6.116

2.  Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.

Authors:  Amanda Gatesman Ammer; Laura C Kelley; Karen E Hayes; Jason V Evans; Lesly Ann Lopez-Skinner; Karen H Martin; Barbara Frederick; Brian L Rothschild; David Raben; Paul Elvin; Tim P Green; Scott A Weed
Journal:  J Cancer Sci Ther       Date:  2009-11-30

3.  Nerve growth factor links oral cancer progression, pain, and cachexia.

Authors:  Yi Ye; Dongmin Dang; Jianan Zhang; Chi T Viet; David K Lam; John C Dolan; Jennifer L Gibbs; Brian L Schmidt
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

4.  Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.

Authors:  Julia S Pettersen; Judilyn Fuentes-Duculan; Mayte Suárez-Fariñas; Katherine C Pierson; Alexander Pitts-Kiefer; Linda Fan; Daniel A Belkin; Claire Q F Wang; Shivaprasad Bhuvanendran; Leanne M Johnson-Huang; Mark J Bluth; James G Krueger; Michelle A Lowes; John A Carucci
Journal:  J Invest Dermatol       Date:  2011-02-10       Impact factor: 8.551

Review 5.  Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Authors:  Jessica M Moskovitz; Jennifer Moy; Tanguy Y Seiwert; Robert L Ferris
Journal:  Oncologist       Date:  2017-05-15

6.  Inflammatory potential of diet and risk of oral and pharyngeal cancer in a large case-control study from Italy.

Authors:  Nitin Shivappa; James R Hébert; Valentina Rosato; Werner Garavello; Diego Serraino; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2017-05-09       Impact factor: 7.396

7.  A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.

Authors:  Kantima Leelahavanichkul; Panomwat Amornphimoltham; Alfredo A Molinolo; John R Basile; Sittichai Koontongkaew; J Silvio Gutkind
Journal:  Mol Oncol       Date:  2013-10-12       Impact factor: 6.603

8.  Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development.

Authors:  R Kesselring; A Thiel; R Pries; T Trenkle; B Wollenberg
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

9.  Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Dae-Young Hong; Byung-Joo Lee; Jin-Choon Lee; Jin-Sik Choi; Soo-Geun Wang; Jung-Hoon Ro
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

Review 10.  Mononuclear phagocytes in head and neck squamous cell carcinoma.

Authors:  Kenneth Wilfried Kross; John-Helge Heimdal; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-05       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.